239 related articles for article (PubMed ID: 27026878)
21. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
Li Z; Fang L; Jiang W; Kim MJ; Zhao L
Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
[TBL] [Abstract][Full Text] [Related]
22. An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong.
Fong JK; Chan EL; Leung H; Chan I; Chang RS; Fong GC; Fung EL; Lui CH; Fung BB; Poon TL; Siu D; Wong HT; Yeung E; Yung AW; Zhu CX;
Hong Kong Med J; 2017 Feb; 23(1):74-88. PubMed ID: 28184017
[TBL] [Abstract][Full Text] [Related]
23. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.
Polard E; Nowak E; Happe A; Biraben A; Oger E;
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769
[TBL] [Abstract][Full Text] [Related]
24. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations.
Shin JW; Chu K; Jung KH; Lee ST; Moon J; Lee SK
Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1017-22. PubMed ID: 25295717
[TBL] [Abstract][Full Text] [Related]
25. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
26. Bioequivalence and other unresolved issues in generic drug substitution.
Meredith P
Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
[TBL] [Abstract][Full Text] [Related]
27. Quality of life after switching to generic levetiracetam - A prospective comparative study.
Olsson P; Reimers A; Källén K
Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
[TBL] [Abstract][Full Text] [Related]
28. Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.
Weitzel J; Erzkamp S; Langer K; Rose O
Int J Clin Pharm; 2020 Apr; 42(2):393-417. PubMed ID: 32274633
[TBL] [Abstract][Full Text] [Related]
29. Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.
Kang J; Park YS; Kim SH; Kim SH; Jun MY
Korean J Physiol Pharmacol; 2011 Apr; 15(2):67-81. PubMed ID: 21660146
[TBL] [Abstract][Full Text] [Related]
30. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
31. Current approaches to the use of generic antiepileptic drugs.
Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G
Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678
[TBL] [Abstract][Full Text] [Related]
32. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
[TBL] [Abstract][Full Text] [Related]
33. The Controversy over Generic Antiepileptic Drugs.
Shaw SJ; Hartman AL
J Pediatr Pharmacol Ther; 2010 Apr; 15(2):81-93. PubMed ID: 22477799
[TBL] [Abstract][Full Text] [Related]
34. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
35. Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.
Barrett MW
J Am Acad Nurse Pract; 2010 Jun; 22(6):300-4. PubMed ID: 20536627
[TBL] [Abstract][Full Text] [Related]
36. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
Le Corre P
Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
[TBL] [Abstract][Full Text] [Related]
37. Brand-to-generic oxcarbazepine switch - A prospective observational study.
Bosak M; Słowik A; Dziedzic T
Epilepsy Res; 2019 Mar; 151():75-77. PubMed ID: 30836239
[TBL] [Abstract][Full Text] [Related]
38. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
39. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
40. [Generic drugs in the treatment of epilepsy].
González de Dios J; Ochoa-Sangrador C; Sempere AP
Rev Neurol; 2005 Dec 1-15; 41(11):676-83. PubMed ID: 16317637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
